Timber Creek Capital Management LLC Increases Stock Position in Elevance Health, Inc. $ELV

Timber Creek Capital Management LLC raised its position in Elevance Health, Inc. (NYSE:ELV) by 32.0% during the third quarter, Holdings Channel.com reports. The fund owned 16,652 shares of the company’s stock after purchasing an additional 4,034 shares during the quarter. Elevance Health accounts for approximately 1.3% of Timber Creek Capital Management LLC’s investment portfolio, making the stock its 29th largest position. Timber Creek Capital Management LLC’s holdings in Elevance Health were worth $5,380,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares during the last quarter. Sanders Capital LLC boosted its holdings in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after acquiring an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership increased its position in Elevance Health by 9.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock valued at $1,429,498,000 after purchasing an additional 324,399 shares during the period. Norges Bank bought a new position in Elevance Health in the 2nd quarter worth $1,148,379,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Elevance Health by 4.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock valued at $788,616,000 after buying an additional 112,020 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Guggenheim decreased their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Barclays decreased their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. UBS Group set a $400.00 price objective on Elevance Health in a research report on Thursday, January 29th. Robert W. Baird lifted their price target on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a report on Tuesday, February 3rd. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Stock Up 3.1%

ELV opened at $346.49 on Tuesday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The stock has a market capitalization of $76.47 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50. The firm has a 50 day moving average price of $352.53 and a 200-day moving average price of $332.74.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same period in the previous year, the business earned $3.84 EPS. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s payout ratio is 27.23%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.